Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with SAEs** compared with placebo (moderate certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).
Angiotensin‐converting enzyme inhibitors showed no clear difference in CVD events: total (fatal and non‐fatal) compared with placebo (low certainty).
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
Statin therapy leads to lower major cardiovascular events (MACE) compared with placebo or standard of care (high certainty).
Statin therapy leads to lower death compared with placebo or standard of care (high certainty).
It is very uncertain whether statin therapy changes rhabdomyolysis compared with placebo or standard of care (very low certainty).
Statin therapy probably leads to lower myocardial infarction compared with placebo or standard of care (moderate certainty).
Statin therapy showed no clear difference in stroke compared with placebo or standard of care (moderate certainty).
Statin therapy showed no clear difference in kidney failure compared with placebo or standard of care (moderate certainty).
Statin therapy showed no clear difference in hospitalisation due to heart failure compared with placebo or standard of care (low certainty).